<DOC>
	<DOCNO>NCT02880618</DOCNO>
	<brief_summary>The purpose registry evaluate effect BAROSTIM THERAPY BAROSTIM NEO System commercial setting subject recently implant CE-Marked indication heart failure reduce ejection fraction ( HFrEF ) .</brief_summary>
	<brief_title>BAROSTIM THERAPY™ Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Has sign EC approve informed consent form Has treat appropriate heart failure guideline direct therapy Has implant BAROSTIM NEO System past 30 day NYHA III , LVEF ≤ 35 % Bilateral carotid bifurcation locate level mandible Baroreflex failure autonomic neuropathy Uncontrolled , symptomatic cardiac bradyarrhythmias Carotid atherosclerosis determine ultrasound angiographic evaluation great 50 % Ulcerative plaque carotid artery determine ultrasound angiographic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Reduced ejection fraction</keyword>
</DOC>